Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Protagonist Therapeutics (PTGX) Depreciation and Depletion: 2014-2024

Historic Depreciation and Depletion for Protagonist Therapeutics (PTGX) over the last 11 years, with Dec 2024 value amounting to $894,000.

  • Protagonist Therapeutics' Depreciation and Depletion rose 8.09% to $254,000 in Q4 2022 from the same period last year, while for Dec 2022 it was $1.0 million, marking a year-over-year increase of 26.94%. This contributed to the annual value of $894,000 for FY2024, which is 8.50% down from last year.
  • Latest data reveals that Protagonist Therapeutics reported Depreciation and Depletion of $894,000 as of FY2024, which was down 8.50% from $977,000 recorded in FY2023.
  • In the past 5 years, Protagonist Therapeutics' Depreciation and Depletion ranged from a high of $1.0 million in FY2022 and a low of $789,000 during FY2020.
  • Over the past 3 years, Protagonist Therapeutics' median Depreciation and Depletion value was $977,000 (recorded in 2023), while the average stood at $967,667.
  • Its Depreciation and Depletion has fluctuated over the past 5 years, first rose by 26.94% in 2022, then decreased by 8.50% in 2024.
  • Over the past 5 years, Protagonist Therapeutics' Depreciation and Depletion (Yearly) stood at $789,000 in 2020, then rose by 3.04% to $813,000 in 2021, then grew by 26.94% to $1.0 million in 2022, then fell by 5.33% to $977,000 in 2023, then declined by 8.50% to $894,000 in 2024.